Skip to content
Open access

Efficacy and Safety of CAR‐T Cell Therapy in Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia With Central Nervous System Involvement

Sep 2026 · Cancer Medicine · Vol 15 · 0 citations · 24 references
Medicine

TL;DR

In conclusion, CAR‐T therapy offers similar efficacy and safety in R/R B‐ALL patients regardless of CNS involvement, and consolidative allo‐HSCT as consolidation post‐CAR‐T as an independent protective factor for improved EFS and OS in CNSL patients.

Abstract

Central nervous system (CNS) involvement in B‐cell acute lymphoblastic leukemia (B‐ALL) is associated with relapse, treatment refractoriness, and poor prognosis. Although chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in relapsed/refractory (R/R) B‐ALL, its efficacy and safety in CNS leukemia (CNSL) remain unclear. We retrospectively analyzed 113 R/R B‐ALL patients who received CAR‐T cell therapy, stratifying them into CNS‐positive (n = 22) and CNS‐negative (n = 91) groups based on the presence of CNSL prior to infusion. At Day 28 after CAR‐T infusion, the overall complete remission (CR) rate was 81.8%, with no significant difference between groups. The incidence of cytokine release syndrome (CRS) and neurotoxicity was comparable. The 3‐year cumulative incidence of relapse (CIR), event‐free survival (EFS), and overall survival (OS) were similar between groups. However, CNSL patients exhibit a higher cumulative relapse rate following CAR‐T‐induced remission, with an increased risk of CNS relapse compared to patients without CNS involvement. Multivariate analysis identified allo‐HSCT as consolidation post‐CAR‐T as an independent protective factor for improved EFS and OS in CNSL patients. In conclusion, CAR‐T therapy offers similar efficacy and safety in R/R B‐ALL patients regardless of CNS involvement. Furthermore, CAR‐T cell therapy was not sufficient to maintain sustained remission, and consolidative allo‐HSCT may improve long‐term survival in this high‐risk group.

Read PDF

Similar papers

Review Open access Oct 2026

Efficacy and Safety of CAR T‐Cell Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review and Meta‐Analysis

Patients with relapsed or refractory primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) have limited treatment options and poor outcomes. CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has shown promising activity in this setting; however, the available e...

Anfal Khan, A. A. Malik, Waqas Kareem et al. · 0 citations
Review Open access Sep 2026

Beyond CAR-T: Preventing and Treating Relapse in B-Cell Haematological Malignancies

Current evidence remains largely preliminary and is limited by the paucity of randomized prospective trials, although relapse management is disease-specific and increasingly incorporates novel therapeutic agents, including bispecific antibodies (BsAbs) and other targeted therapies.

Martina Canichella, E. Abruzzese, Mariagiovanna Cefalo et al. · 0 citations
Open access Sep 2026

Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL

Abstract Background CD19-targeting chimeric antigen receptor T-cells (CAR-T) and blinatumomab represent two leading immunotherapies for relapsed/refractory B cell acute lymphoblastic leukemia (r/r B-ALL). Despite sharing the same target, their differential clinical efficacy and underlying mechanisms remain unclear. Met...

Ke-Xin Wang, Lei Yu, Xing-Hua Liang et al. · 0 citations
Open access Sep 2026

Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients

Donor-derived anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy has emerged as one of the most promising treatments for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In this retrospective study, we evaluated the safety and efficacy of donor-derived anti-CD19 CAR T cells manufactur...

Supavich Tannumsaeng, U. Anurathapan, Arpatsorn Sermcheep et al. · 0 citations
Case report Open access Sep 2026

Case Report: Clinical response to TKI therapy in T-cell acute lymphoblastic leukemia with rare ABL1 rearrangement

Background T-cell acute lymphoblastic leukemia (T-ALL) with ABL1 rearrangement is an extremely rare disease, and its clinical significance has not been precisely defined. We report the clinical characteristics of a pediatric patient with T-cell acute lymphoblastic leukemia harboring ABL1 rearrangement and the treatment...

Ming-Yan Zhong, Wen-Ting He, Ling-Ji Zeng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.